Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3. Clinical activity of xaluritamig in evaluable patients. A, Best PSA percentage change from baseline. Asterisk indicates confirmed PSA responders, and dashed lines indicate PSA50 and PSA90 declines. B, Best percentage change in size of tumor target lesions. Dashed line indicates 30% reduction in tumor SLD from baseline. C, Example of patient showing response by PSA and radiographic assessments: CT scan and PSA curve over time of a heavily pretreated 65-year-old patient with stage IV prostate adenocarcinoma. Patient was enrolled into Cohort 11 (3-step 1.5 mg target dose of xaluritamig). CT scans showed three target lesions (two liver, one lymph node) and multiple nontarget lesions in the liver as well as two lymph nodes during screening. Patient achieved 99% PSA decline from baseline on C7D1 and PR (37.3% reduction of target lesions) after 2 cycles, which was confirmed at 16 weeks and maintained after 24 weeks. AEs occurred during C1 of treatment and included recurrent CRS, tinea faciei (both grade 1), rash, and worsening of back pain (both grade 2). During further treatment cycles, rash (grade 1), myalgia, and hyperkalemia (both grade 2) were reported. Patient remains on treatment at the time of publication. Red arrows indicate sites of tumor. D, Time on treatment for patients in high-dose cohorts. PSA and RECIST responses [RECIST evaluable (gray bars) and non–RECIST evaluable (white bars)] are presented for patients in high-dose cohorts. Patients whose treatment was ongoing are noted by an arrowhead. Double parallel lines (//) represent patients who have extended beyond 48 weeks: one patient is ongoing treatment at 90 weeks, one is ongoing treatment at 84 weeks, and one ended treatment at 58 weeks. NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of longest diameters.](https://figures.cochat.ai/paper-figures/f36f247450c445ae9fdf56ba95743352/xaluritamig-a-steap1-cd3-xmab-2-1-immune-therapy-for-metastatic-castration-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A PSA50 response was observed in 49% of patients, and a PSA90 response was observed in 30%, supporting the need for further development.”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Regarding this drug candidate’s safety profile, CRS occurred in 72% of patients, primarily during cycle 1, with other less common side effects including myalgia, myofascitis, and maculopapular rash. CRS events improved with premedication and step dosing, and only 3% of patients ultimately discontinued due to this”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationOverall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206913 · Cited by 761
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
Cited by
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00690-x · Cited by 248
Nolan-Stevaux, O., & Smith, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490911 · Cited by 100
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2978 · Cited by 76
Self-citationZaidi, S., Park, J., Chan, J. M., Roudier, M. P., Zhao, J. L., Gopalan, A., Wadosky, K. M., Patel, R. A., Sayar, E., Karthaus, W. R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322203121 · Cited by 77
Metadata
- Authors
- Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., Fischer, S., Lin, Y.-C., Horvath, L. G., Sumey, C., Yang, Z., Jurida, G., Smith, K. M., Connarn, J. N., Penny, H. L., Stieglmaier, J., & Appleman, L. J.
- Affiliations
- Thomas Jefferson University (US)
- Memorial Sloan Kettering Cancer Center (US)
- National Taiwan University Hospital (TW)
- Asan Medical Center (KR)
- 7National Cancer Center Hospital East, Chiba, Japan.
- Sarah Cannon (US)
- Duke University (US)
- Monash Health (AU)
- Seoul National University (KR)
- City Of Hope National Medical Center (US)
- Kantonsspital St. Gallen (CH)
- Linkou Chang Gung Memorial Hospital (TW)
- The University of Sydney (AU)
- 16Sanford Cancer Center, Sioux Falls, South Dakota.
- Amgen (United States) (US)
- Amgen (Germany) (DE)
- UPMC Health System (US)
- Corresponding author
- Kelly, William K.
- ORCID
- Kelly, William K.
- Danila, Daniel C.
- Lin, Chia-Chi
- Lee, Jae-Lyun
- Matsubara, Nobuaki
- Ward, Patrick J.
- Armstrong, Andrew J.
- Pook, David
- Kim, Miso
- Dorff, Tanya B.
- Fischer, Stefanie
- Lin, Yung-Chang
- Horvath, Lisa G.
- Sumey, Christopher
- Yang, Zhao
- Jurida, Gabor
- Smith, Kristen M.
- Connarn, Jamie N.
- Penny, Hweixian L.
- Stieglmaier, Julia
- Appleman, Leonard J.
- Venue
- Cancer Discovery
- Published
- 2023-10-20
- Volume
- 14
- Issue
- 1
- Pages
- 76-89
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC10784743
- OpenAlex
- W4387798677
- Cited by
- 125
- References
- 30
- Citations by year
- 2026: 56 · 2025: 47 · 2024: 21 · 2023: 1
- FWCI
- 23.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- STEAP1, T-cell engagers, metastatic castration-resistant prostate cancer, dose escalation, maximum tolerated dose, cytokine release syndrome, taxane-pretreated patients, PSA response, RECIST response
- MeSH terms
- Antigens, Neoplasm, Humans, Immunotherapy, Male, Oxidoreductases, Treatment Outcome, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. https://app.cochat.ai/papers/10.1158/2159-8290.cd-23-0964
- The paper
- Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., Fischer, S., Lin, Y.-C., Horvath, L. G., Sumey, C., Yang, Z., Jurida, G., Smith, K. M., Connarn, J. N., Penny, H. L., . . . Appleman, L. J. (2024). Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0964
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.